Immunostimulant

1 marketed 1 in Phase 3 1 in Phase 2

This page covers all Immunostimulant drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Immune cell activation (non-specific), Dectin-1, Complement Receptor 3 (CR3), TLR9.

Targets

Immune cell activation (non-specific) · Dectin-1, Complement Receptor 3 (CR3) · TLR9

Marketed (1)

Levagen+ · RDC Clinical Pty Ltd · Dermatology / Wound Care
Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms.

Phase 3 pipeline (1)

Soluble beta-glucan (SBG) · Biotec Pharmacon ASA · Immunology
Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk.

Phase 2 pipeline (1)

CpG-ODN · Assistance Publique - Hôpitaux de Paris · Immunology
CpG-ODN is a synthetic DNA molecule that acts as an immunostimulant by activating the immune system through Toll-like receptor 9 (TLR9).